Sign Out
Dosage: Individuals 4 years to 60 years of age at time of first injection: Qdenga should be administered as a 0.5 mL dose at a two-dose (0 and 3 months) schedule.
The need for a booster dose has not been established.
Special Patient Populations: Elderly Patients: The safety and efficacy of Qdenga in subjects above 60 years of age has not been established.
Pediatric Patients: The safety and efficacy of Qdenga in children aged less than 4 years has not yet been established.
Currently available data are described in Adverse Reactions but no recommendation on a posology can be made.
Impaired Renal Function: The safety and efficacy of Qdenga in this population not been established.
Impaired Hepatic Function: The safety and efficacy of Qdenga in this population not been established.
Method of administration: After complete reconstitution of the lyophilized vaccine with the diluent (solvent), Qdenga should be administered by subcutaneous (SC) injection preferably in the upper arm in the region of deltoid.
Qdenga must not be injected intravascularly, intradermally or intramuscularly. The vaccine should not be mixed in the same syringe with any vaccines or other parenteral medicinal products.
For instructions on reconstitution of Qdenga before administration, see Instructions for Use/Handling under Cautions for Usage.
